(a) Hairy cell morphology at second relapse; (b) TRAP staining of hairy cells at second relapse; (c) multinucleate hairy cells at third relapse; (d) Western blot demonstrating no differences in phospho-ERK levels between untreated (lane 1) and PLX4720 treated (lane 2) cells; (e) wild-type sequence of patient BRAF exon 15.